-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicenna Presents MDNA209 Preclinical Data at Promises of Treg and Interleukin-2 Therapies Conference

PUBT·10/22/2026 11:08:36
Listen to the news
Medicenna Presents MDNA209 Preclinical Data at Promises of Treg and Interleukin-2 Therapies Conference
  • Medicenna will present preclinical data on CD122 antagonist MDNA209 at the Promises of Treg and Interleukin-2 Therapies Conference.
  • The conference runs Oct. 21-24, 2026, in Paris; the presentation is scheduled for Oct. 23, 4:30-5 p.m. CEST.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220700PRIMZONECNPR____9851060) on October 22, 2026, and is solely responsible for the information contained therein.